ATATcH Alternating Treatment Plans for Advanced Cancer

The purpose of the research is to evaluate a new schedule of alternating cycles of induction chemoimmunotherapy (chemotherapy plus pembrolizumab) and immunotherapy (pembrolizumab) alone for the initial treatment of patients with advanced lung or head and neck cancers.

Trial Details

NCT ID
NCT05358548
Phase
PHASE2
Sponsor
Rutgers, The State University of New Jersey
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • Paclitaxel
  • Pemetrexed
  • 5Fluorouracil
  • Carboplatin
  • Pembrolizumab
Locations (sample)
  • Elizabeth, New Jersey, United States|40.66399,-74.2107
  • Hamilton, New Jersey, United States|40.20706,-74.08125
  • Jersey City, New Jersey, United States|40.72816,-74.07764
  • Lakewood, New Jersey, United States|40.09789,-74.21764
  • Livingston, New Jersey, United States|40.79593,-74.31487

Key Eligibility Criteria

  • Lung Cancer (Arms 1 and 2)
  • Patients must have histologically or cytologically confirmed stage IV NSCLC (includes M1a, M1b, and M1c stage disease, AJCC 8th edition). Patients …
  • Eligible NSCLC tissue histologies will include squamous cell carcinoma (enrolled and treated in Arm 1), and nonsquamous histologies (e.g. adenocarc…
  • Patients may have ANY PD-L1 expression Tumor Proportion Score (TPS) status. Tissue testing for PD-L1 is strongly recommended. If PD-L1 expression T…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →